We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

25 hedge funds and large institutions have $184M invested in POINT Biopharma Global Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 4 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more funds holding

Funds holding: 18 → 25 (+7)

1% less capital invested

Capital invested by funds: $186M → $184M (-$1.21M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
25
Holders Change
+7
Holders Change %
+38.89%
% of All Funds
0.44%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
–
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SPC
Sigma Planning Corp
Michigan
+$159K
2
Wells Fargo
Wells Fargo
California
+$27.8K
3
WAM
Wolverine Asset Management
Illinois
+$14.2K
4
UBS Group
UBS Group
Switzerland
+$13.2K
5
Osaic Holdings
Osaic Holdings
Arizona
+$1.39K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$625K
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$428K
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$13.3K
4
Citadel Advisors
Citadel Advisors
Florida
-$9.09K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$20.9M – – –
BC
2
Boxer Capital
California
$20.9M – – –
PA
3
Perceptive Advisors
New York
$20.9M – – –
ACA
4
Avoro Capital Advisors
New York
$13.9M – – –
Franklin Resources
5
Franklin Resources
California
$13.9M – – –
BCLSI
6
Bain Capital Life Sciences Investors
Massachusetts
$13.9M – – –
BI
7
BVF Inc
California
$13.3M -$625K -45,004 -5%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$12.9M – – –
Wellington Management Group
9
Wellington Management Group
Massachusetts
$12.2M -$428K -30,839 -3%
Citadel Advisors
10
Citadel Advisors
Florida
$6.98M -$9.09K -655 -0.1%
CAM
11
Cormorant Asset Management
Massachusetts
$6.97M – – –
LGM
12
Logos Global Management
California
$6.96M – – –
RI
13
RTW Investments
New York
$6.82M – – –
FCMI
14
Foresite Capital Management IV
California
$4.87M – – –
FCMV
15
Foresite Capital Management V
California
$4.87M +$4.86M +350,000 New
Janus Henderson Group
16
Janus Henderson Group
United Kingdom
$1.73M -$13.3K -959 -0.8%
TD Asset Management
17
TD Asset Management
Ontario, Canada
$687K – – –
MIM
18
Monashee Investment Management
Massachusetts
$658K – – –
SCM
19
Silverarc Capital Management
Massachusetts
$543K +$542K +39,009 New
SFM
20
Sphera Funds Management
Israel
$279K – – –
SPC
21
Sigma Planning Corp
Michigan
$159K +$159K +11,450 New
Wells Fargo
22
Wells Fargo
California
$28K +$27.8K +2,000 New
WAM
23
Wolverine Asset Management
Illinois
$14K +$14.2K +1,025 New
UBS Group
24
UBS Group
Switzerland
$13K +$13.2K +948 New
Osaic Holdings
25
Osaic Holdings
Arizona
$1K +$1.39K +100 New

PNT Hedge Fund Activity: Q4 2020 in Review

25 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2020, worth a combined $184M — down 0.65% from $186M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PNT positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 4 trimmed.

The largest buyer was Sigma Planning Corp, opening a new position worth an estimated $159K. The largest seller was BVF Inc, cutting an estimated $625K.

  • 25 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2020, up from 18 in Q3 2020.
  • Funds reported $184M of POINT Biopharma Global Inc. Common Stock stock for Q4 2020, down 0.65% quarter-over-quarter.
  • 7 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +7 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2020 was Sigma Planning Corp, an estimated $159K added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2020 was BVF Inc, an estimated $625K sold.

Based on aggregated 13F filings for Q4 2020.